Title: Relating Activating K-Ras Mutations to Small Molecule Sensitivity in Non-Small-Cell Lung Cancer
1Relating Activating K-Ras Mutations to Small
Molecule Sensitivity in Non-Small-Cell Lung
Cancer
- Flavian D. Brown
- Carleton College
- Class of 2009
2Lung Cancer
- Leading cause of death from cancer in the world
- Over 90 of NSCLC contain mutations in EGFR,
BRAF and K-Ras - Discovery of Gefitnib
3Ras Signaling
Oncogenic Mutation
?
?
Oncogenic Mutation
?
Schubbert et al. (2007) Hyperactive Ras in
developmental disorders and cancer. Nature Review
of Cancer, Vol. 7 295-307.
4Hypothesis
- NSCLC tumors are genetically sensitized due to
changes in cellular state secondary to activating
K-Ras mutations. - - Different drug targets
- - Oncogene Addiction
-
5Small Molecule Screens
6Hits From Primary Screen
A549 Hits Highlighted Color coding on the
images Red unbiased commercial compound Forma
setGreen bioactives (including kinase
inhibiting drugs)Magenta HDAC biased DOSBlue
commercial kinase biased (CBkinase)Yellow
analyticon purified natural productsBlack DMSO
control plateGray con dose plate
7Assay Development
8Small Molecule Sensitivity
9Small Molecule Sensitivity
10Small Molecule Sensitivity
11Structural Activity Relationship
Aromatic group at the opposite end of structures
Carbon spacer can be rigid or flexible
Hydroxamic acids attached to a 4 or 5 carbon chain
12Future Investigations
- Analyze signaling downstream of the activating
mutation - -Immunofluorescence
- -Western Blotting
- Target Identification
- - Pull down assay
- Correlate phenotypic data with genetic data
- - SNP copy number
13Impact
- Genotype specific inhibitors for K-Ras mutants
- Paradigm for investigating genotype-phenotype
relationships in other malignancies - - WGAS for somatic alterations
- Molecularly targeted cancer therapeutics.
-
14Acknowledgements
- Principle Investigator
- Stuart L.Schreiber, Ph.D
- Mentor
- Gopal S. Ramachandran, Ph.D
- Summer Research Program in Genomics
- Shawna Young
- Lucia Vielma
- Maura L. Silverstein
- Bruce Birren, Ph.D
- Collaborators
- - Jordi Barretina, Ph.D
- - Damian W. Young, Ph.D
- Broad Institute Screening
- Nicola Tolliday, Ph.D
- Josh Bittker, Ph.D
- Melanie de Silva
- Kate Hartland
15References
- Arcaro, A. The small GTP-binding protein Rac
promotes the dissociation of gelsolin from actin
filaments in neutrophils. J. Biol.Chem. 273,
805813 (1998) - Bourne, H. R., Sanders, D. A. McCormick, F. The
GTPase superfamily a conserved switch for
diverse cell functions. Nature 348, 125132
(1990). - Diaz et al. Complex effects of Ras
proto-oncogenes in tumorigenesis. Carcinogenesis,
Vol. 25, No. 4, 535-539 (2004). - Downward, J. Targeting RAS signaling pathways in
cancer therapy. Nature Rev. Cancer 3, 1122
(2003). - Gibbs, J. B. Oliff, A. The potential of
farnesyltransferase inhibitors as cancer
chemotherapeutics. Annu. Rev. Pharmacol. Toxicol.
143166 (1997). - Herrmann, C. Raseffector interactions after one
decade. Curr. Opin. Struct. Biol. 13, 122129
(2003) - Lynch et al. Activating mutations in the
epidermal growth factor receptor underlying
responsiveness of non-small-cell lung cancer to
gefitinib. The New England Journal of Medicine.
Vol. 350 No.21, 2129-2139. (2004) - Paez, et al. EGFR Mutations in Lung Cancer
Correlation with Clinical Response to Gefitinib
Therapy. Science. 304, 1497 (2004). - Repasky, G. A., Chenette, E. J. Der, C. J.
Renewing the conspiracy theory debate does Raf
function alone to mediate Ras oncogenesis? Trends
Cell Biol. 14, 639647 (2004). - Schubbert et al. Hyperactive Ras in developmental
disorders and cancer. Nature, Vol. 7 295-307.
(2007) - Swanson et al. Raymond, J. Hohl. Anti-Cancer
Therapy Targeting the Mevalonate. Current Cancer
Drug Target 2006, 6, 15-37 - Vetter, I. R. Wittinghofer, A. The guanine
nucleotidebinding switch in three dimensions.
Science 294, 12991304 (2001). - Zhang et al. Knockdown of Mutant K-ras Expression
by Adenovirus-Mediated siRNA Inhibits the In
Vitro and in Vivo Growth of Lung Cancer Cells.
Cancer Biology and Therapy 1481-1486 (2006) - Zhang et al. Silencing the epidermal growth
factor receptor gene with RNAi may be developed
as a potential therapy for non small lung cancer.
Genetic Vaccines and Therapy 35 (2005)